XFOR Company Profile and Key Details

Q: Who are the executives of XFOR?

Dr. Robert David ArbeitSenior Vice President of Clinical Devel. and Translational ResearchDr. Keith T. Flaherty M.D.Founder & Member of Corporation Advisory BoardMr. Mark Baldry M.B.A.Chief Commercial OfficerDr. Mary DiBiase Ph.D.Chief Operating OfficerDr. Richard Peters M.D., Ph.D.FounderDr. Murray W. Stewart M.D.Interim Chief Medical Officer & DirectorDr. Renato T. Skerlj Ph.D.FounderDr. Arthur Taveras Ph.D.Chief Scientific OfficerMr. Adam S. MostafaManaging DirectorDr. Paula Ragan Ph.D.Chief Executive Officer, Pres & Director

NASDAQ : XFOR

X4 Pharmaceuticals

$4.12

-0.1-2.37%

At Close 4:00 PM

61.68

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

X4 Pharmaceuticals, Inc. (XFOR) stock declined over -2.37%, trading at $4.12 on NASDAQ, down from the previous close of $4.22. The stock opened at $4.27, fluctuating between $4.12 and $4.43 in the recent session.

Stock Snapshot

4.22

Prev. Close

388.6M

Market Cap

4.115

Day Low

-1.98

P/E Ratio

-2.08

EPS (TTM)

-0.46

Cash Flow per Share

4.27

Open

94.32M

Number of Shares

4.425

Day High

71.51%

Free Float in %

0.26

Book Value

437.3K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	4.22	4.43	4.11	4.12	438.07K
Jun 18, 2026	4.03	4.28	4.01	4.22	866.23K
Jun 17, 2026	4.06	4.11	3.99	4.05	403.78K
Jun 16, 2026	4.10	4.14	3.99	4.04	460.29K
Jun 15, 2026	4.03	4.12	4.00	4.08	562.31K
Jun 12, 2026	3.93	4.02	3.90	4.00	501.53K
Jun 11, 2026	3.71	3.89	3.67	3.88	471.52K
Jun 10, 2026	3.84	4.00	3.72	3.73	399.64K
Jun 09, 2026	3.71	3.95	3.71	3.85	434.52K
Jun 08, 2026	3.91	3.95	3.66	3.71	451.73K
Jun 05, 2026	4.00	4.02	3.76	3.83	445.23K
Jun 04, 2026	3.95	4.17	3.95	4.01	276.97K
Jun 03, 2026	4.04	4.09	3.96	3.97	398.55K
Jun 01, 2026	4.24	4.33	4.10	4.11	468.41K
May 29, 2026	4.12	4.36	4.05	4.31	878.02K
May 28, 2026	4.01	4.18	3.99	4.14	296.34K
May 27, 2026	3.98	4.16	3.98	4.03	213.39K
May 26, 2026	4.07	4.15	3.97	4.00	287.67K
May 22, 2026	4.05	4.20	4.00	4.04	177.16K
May 21, 2026	3.71	4.07	3.71	4.04	254.69K

Contact Details

Boston, MA 02134

United States

https://www.x4pharma.com 857 529 8300

About Company

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) closed at $4.12 USD, losing -$0.10 (-2.37%) from the previous close of $4.22. The stock is currently mid-range between its 52-week high and low $1.35 and $4.83. With a market capitalization of about $388.60 million, X4 Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.37). Key stats such as the average daily volume over the past year has been around 402.19 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, X4 Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adam R. Craig, the company employs approximately 143 people and listed since November 16, 2017. X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -6.47%, SMA50 -12.52%, SMA200 1.61%). The stock’s 14-day RSI is 42.39 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.98% below its high and over 140.74% above its low. Average 10-day trading volume of 546.13 thousand shares is slightly above the 3-month average of 396.14 thousand, indicating heightened recent market interest.

Valuation Metrics

X4 Pharmaceuticals, Inc. trades at a P/E ratio of -0.94, slightly below the S&P 500 average, with a price-to-sales ratio of 44.89 and a price-to-book ratio of 3.22 trading at moderately above to book value. The P/FCF stands at -5.52, also below market averages.

Dividend & Fair Value

X4 Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.65. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

X4 Pharmaceuticals, Inc. generated EPS of -$10.01 over the past year. Five-year average earnings growth is 47.41%. Wall Street analysts project EPS growth of 48.4% annually over the next five years. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.25. Next year's EPS is expected at $34.15. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $3.50. The high target offers 191.26% upside. The low target suggests -15.05% downside. The mean target is $8.58. This offers 108.25% upside. X4 Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by -23.81%. The prior quarter beat by -38.89%. Over the last six quarters, Apple has recorded several small beats. These include 17.61% in March 25, 2025.

Shareholding & Insider Activity

X4 Pharmaceuticals, Inc. has 22.45 million shares outstanding. The public float is 8.16 million shares, elevated short interest at 6.95% of float. This equals 1.55 million shares. The short ratio is 0.17 days. Institutional investors hold 100.17% of the float. Insiders own 0.54%. SVLSF V, LLC holds 1.85 million shares, Ragan Paula has 1.09 million shares and NeoMed Innovation V L.P. has 867.64 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.96 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, X4 Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -68.70% and ROE at -197.98%.
On valuation metrics, X4 Pharmaceuticals trades at a P/E of -0.94, P/S of 44.89 and P/B of 3.22. The current ratio is 10.18 and quick ratio is 9.98. Operationally, the company’s inventory turnover is 0.40 and cash conversion cycle is -40.81 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.46, supported by a cash flow-to-debt ratio of -1.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, X4 Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $2.00M (margin 0.00%). Operating income was - $107.52M (margin 0.0%). Net income was- $101.17M (EPS - $0.57).
The company ended the quarter with $114.47M in cash and short-term investments, a total debt of $58.28M, and net debt of - $41.19M. Total assets were $147.26M, with equity of $51.10M. Financials further reflected weakness, with operating cash flow of - $96.51M, free cash flow of - $96.57M, and capital expenditures of - $60.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that X4 Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.7%, with price expected at $4.05 by July 06, 2026, within a range of $3.81 to $4.29 3-Month Outlook: Projected fall of -62.86%, reaching $1.53 by September 16, 2026, with a range of $0.94 to $1.85. 1-Year Outlook: Projected gain of 106.55%, with price at $8.51 by June 22, 2027, within a range of $0.00 to $6.38.

Key Takeaways

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) shares are flat -8.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows X4 Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.94. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $7.35, suggesting 78.4% upside. Our AI forecast model points to short-term weakness (-1.7% over two weeks), a medium-term fall (-62.86% over three months), and a longer-term gain (106.55% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current X4 Pharmaceuticals, Inc. (XFOR) stock price?

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) stock price is $4.12 in the last trading session. During the trading session, XFOR stock reached the peak price of $4.43 while $4.12 was the lowest point it dropped to. The percentage change in XFOR stock occurred in the recent session was -2.37% while the dollar amount for the price change in XFOR stock was - $0.10.

XFOR's industry and sector of operation?

The NASDAQ listed XFOR is part of Biotechnology industry that operates in the broader Healthcare sector. X4 Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of XFOR?

Dr. Robert David Arbeit
Senior Vice President of Clinical Devel. and Translational Research
Dr. Keith T. Flaherty M.D.
Founder & Member of Corporation Advisory Board
Mr. Mark Baldry M.B.A.
Chief Commercial Officer
Dr. Mary DiBiase Ph.D.
Chief Operating Officer
Dr. Richard Peters M.D., Ph.D.
Founder
Dr. Murray W. Stewart M.D.
Interim Chief Medical Officer & Director
Dr. Renato T. Skerlj Ph.D.
Founder
Dr. Arthur Taveras Ph.D.
Chief Scientific Officer
Mr. Adam S. Mostafa
Managing Director
Dr. Paula Ragan Ph.D.
Chief Executive Officer, Pres & Director

How XFOR did perform over past 52-week?

XFOR's closing price is 205.19% higher than its 52-week low of $1.35 where as its distance from 52-week high of $4.83 is -14.7%.

How many employees does XFOR have?

Number of XFOR employees currently stands at 143.

Link for XFOR official website?

Official Website of XFOR is: https://www.x4pharma.com

How do I contact XFOR?

XFOR could be contacted at phone 857 529 8300 and can also be accessed through its website. XFOR operates from 61 North Beacon Street, Boston, MA 02134, United States.

How many shares of XFOR are traded daily?

XFOR stock volume for the day was 437.3K shares. The average number of XFOR shares traded daily for last 3 months was 402.19K.

What is the market cap of XFOR currently?

The market value of XFOR currently stands at $388.60M with its latest stock price at $4.12 and 94.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	143
Beta	0.37
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

XFOR Company Profile and Key Details

X4 Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook